Evidence map›Paper›PMID 41362860›Full record

ArticleJAAD case reports2026

Successful treatment of an

Afsaneh Sadeghzadeh-Bazargan, Nastaran Khodakarim, Meysam Nazari Liafuii, Roya Zeinali, Alireza Safaei, Leila Youssefian, Abbas Dehghani, Hassan Vahidnezhad

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JAAD case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Afsaneh Sadeghzadeh-BazarganDepartment of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Nastaran KhodakarimDepartment of Medical Oncology and Hematology, Hazrat Rasoul Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Meysam Nazari LiafuiiDepartment of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Roya ZeinaliDepartment of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Alireza SafaeiDepartment of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Leila YoussefianDepartment of Pathology, Cytogenetics Laboratory, City of Hope National Medical Center, Irwindale, California.
Abbas DehghaniDepartment of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hassan VahidnezhadDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

EGFR inhibitorsErlotinibMBTPS2Olmsted syndrome

Identifiers

PMID41362860
PMCPMC12682031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.